Search

Displaying results 2541 - 2550 of 8696 in total
  1. Drug

    Dirucotide

    go.drugbank.com/drugs/DB04921
    Investigational

    Dirucotide has been developed for the treatment of multiple sclerosis (MS). Developed at the University of Alberta, dirucotide is being investigated by BioMS Medical Corp.

  2. Drug

    Turoctocog alfa pegol

    go.drugbank.com/drugs/DB14738
    ApprovedInvestigational

    This modification to the general turoctocog alfa rFVIII structure makes N8-GP an extended half-life factor VIII molecule for factor VIII replacement therapy in patients with factor VIII deficiency, or … that is less frequent than that for turoctocog alfa.

  3. Drug

    Prademagene zamikeracel

    go.drugbank.com/drugs/DB17895
    ApprovedInvestigational

    [L53013] It was granted an Orphan Drug designation by the EMA.[A273833] … [L53008] COL7A1 encodes type VII collagen (C7), which is a major component of anchoring fibrils (AF) that are critical for dermal-epidermal cohesion.

  4. Drug

    Oxiconazole

    go.drugbank.com/drugs/DB00239
    Approved

    Oxiconazole is an antifungal agent that is commonly found in topical formulations.

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
  5. Indication

    Anticholinergic Syndrome

    go.drugbank.com/conditions/DBCOND0005987
    Drugs: Physostigmine
    Synonyms: Poisoning caused by acetylcholine receptor antagonist, Poisoning caused by acetylcholine receptor antagonist (disorder)
  6. Drug

    Canagliflozin

    go.drugbank.com/drugs/DB08907
    ApprovedInvestigational

    It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type … Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes [L5897].

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  7. Drug

    Deferasirox

    go.drugbank.com/drugs/DB01609
    ApprovedInvestigational

    Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP1A2 Inhibitors
  8. Drug

    Molibresib

    go.drugbank.com/drugs/DB16239
    Investigational

    Molibresib is under investigation in clinical trial NCT01943851 (A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects

  9. Drug

    Paritaprevir

    go.drugbank.com/drugs/DB09297
    ApprovedInvestigational

    Paritaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). … First approved in December 2014, Viekira Pak is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with [DB00811] for the treatment of HCV

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  10. Drug

    Calaspargase pegol

    go.drugbank.com/drugs/DB14730
    ApprovedInvestigational

    Calaspargase pegol, also known as _asparlas_, is an asparagine specific enzyme which is indicated as a part of a multi-agent chemotherapy regimen for the treatment of ALL [L4890]. … Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) [A40270].